Regional Health Propsの空売り状況は、投資家がRegional Health Propsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Regional Health Props (AMEX:RHE) 株価情報, 空売り情報

Regional Health Props

Regional Health Properties Inc is a self-managed healthcare real estate investment company that invests in real estate purposed for senior living and long-term healthcare through facility lease and sub-lease transactions. It has two reportable segments real estate segment and the healthcare services segment. It derives the majority of its revenue from the healthcare services segment. Its portfolio of properties is diversified across various states, with concentrations in Georgia and Ohio.

Regional Health Properties, Inc. Common Stock

Regional Health Properties Inc

REGIONAL HLTH PPTY B PFD by Regional Health Properties, Inc.

Regional Health Properties, Inc. 10.875% Series A Cumulative Redeemable Preferred Stock

Rheinmetall AG

RHEINMETALL AG UNSP/ADR by Rheinmetall AG

RHEON AUTO MACHINE CO LTD by Rheon Automatic Machinery Co Ltd.

Rheon Automatic Machinery Co Ltd

<p>JP Morgan  analyst Jeffrey Zekauskas   maintains RPM Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPM#NYSE">RPM</a>) with a Neutral and lowers the price target from $126 to $124.</p>


News

Price Target

Analyst Ratings

JP Morgan Maintains Neutral on RPM Intl, Lowers Price Target to $124

<p>JP Morgan  analyst Matthew Boss   maintains Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) with a Overweight and raises the price target from $425 to $428.</p>


LULU

JP Morgan Maintains Overweight on Lululemon Athletica, Raises Price Target to $428

<p>JP Morgan  analyst Matthew Boss   maintains Macy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) with a Overweight and lowers the price target from $21 to $20.</p>


JP Morgan Maintains Overweight on Macy's, Lowers Price Target to $20

<p>JP Morgan  analyst Matthew Boss   maintains Urban Outfitters (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) with a Neutral and raises the price target from $46 to $54.</p>


URBN

JP Morgan Maintains Neutral on Urban Outfitters, Raises Price Target to $54

<p>JP Morgan  analyst Matthew Boss   maintains Five Below (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) with a Underweight and lowers the price target from $110 to $107.</p>


FIVE

JP Morgan Maintains Underweight on Five Below, Lowers Price Target to $107

<p><strong>American Intl Gr's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>) short percent of float has risen 4.6% since its last report. The company recently reported that it has <strong>10.38 million shares sold short</strong>, which is 1.82% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.53 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>American Intl Gr Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736365523_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for American Intl Gr has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing American Intl Gr's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, American Intl Gr's peer group average for short interest as a percentage of float is 1.52%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

Trading Ideas

Looking Into American Intl Gr's Recent Short Interest

<p><strong>Candel Therapeutics's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NYSE">CADL</a>) short percent of float has risen 36.6% since its last report. The company recently reported that it has <strong>4.57 million shares sold short</strong>, which is 13.25% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 1.0 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Candel Therapeutics Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736365517_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Candel Therapeutics has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Candel Therapeutics's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Candel Therapeutics's peer group average for short interest as a percentage of float is 13.75%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


CADL

How Is The Market Feeling About Candel Therapeutics?

<p>JP Morgan  analyst Matthew Boss   maintains Boot Barn Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOOT#NYSE">BOOT</a>) with a Overweight and raises the price target from $181 to $188.</p>


BOOT

JP Morgan Maintains Overweight on Boot Barn Holdings, Raises Price Target to $188

<p><strong>SharkNinja's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SN#NYSE">SN</a>) short percent of float has fallen 15.53% since its last report. The company recently reported that it has <strong>2.70 million shares sold short</strong>, which is 4.35% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.53 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>SharkNinja Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736365512_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for SharkNinja has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing SharkNinja's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, SharkNinja's peer group average for short interest as a percentage of float is 7.10%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Looking Into SharkNinja's Recent Short Interest

<p>JP Morgan  analyst Matthew Boss   maintains American Eagle Outfitters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEO#NYSE">AEO</a>) with a Neutral and lowers the price target from $23 to $20.</p>


JP Morgan Maintains Neutral on American Eagle Outfitters, Lowers Price Target to $20

<p>Jefferies  analyst Julien Dumoulin-Smith   initiates coverage on MDU Resources Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDU#NYSE">MDU</a>) with a Hold rating and announces Price Target of $18.</p>


Initiation

Jefferies Initiates Coverage On MDU Resources Gr with Hold Rating, Announces Price Target of $18

<p>Jefferies  analyst James Heaney   maintains AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) with a Buy and raises the price target from $400 to $425.</p>


Jefferies Maintains Buy on AppLovin, Raises Price Target to $425

<p>Guggenheim  analyst Michael Schmidt   maintains SpringWorks Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>) with a Buy and lowers the price target from $80 to $78.</p>


SWTX

Guggenheim Maintains Buy on SpringWorks Therapeutics, Lowers Price Target to $78

<p>Unease about inflation's persistence and potential policy shifts under a new White House administration dominated the Federal Reserve's December meeting, leaving policymakers divided on the pace <a href="https://www.benzinga.com/topic/interest-rates">of future rate adjustments.</a></p>
<p>Minutes from the Dec. 18 Federal Reserve meeting that were released Wednesday paint a cautious picture of the central bank's outlook on inflation and interest rates.</p>
<p>The Fed cut rates by 25 basis points at the meeting, bringing the federal funds rate to 4.25%-4.5%, and emphasized the path ahead would require a delicate balance between curbing inflation and supporting economic growth.</p>
<p>&#8220;Participants indicated that the Committee was at or near the point at which it would be appropriate to slow the pace of policy easing,&#8221; according to the Fed&#8217;s December minutes. </p>
<p>The minutes also highlight rising uncertainty about inflation and the broader economy, particularly as fiscal and trade policies face potential shifts under the incoming <strong>Donald Trump</strong> administration.</p>
<h3 class="wp-block-heading">Why Is Inflation Anxiety Rising Again?</h3>
<p>While inflation has shown signs of moderating, "recent higher-than-expected readings on inflation" suggest it could take longer to return to the 2% target, the minutes say.</p>
<p>Cleveland Fed President <strong>Beth Hammack </strong>was the sole dissenting vote against an interest rate cut in December, favoring an unchanged rate target of 4.5%-4.75%.</p>
<p>Hammack indicated "uneven progress" toward the Fed's inflation target, alongside robust labor market and economic conditions, as key reasons not to cut interest rates further.</p>
<p>The prospect of significant policy shifts under Trump has left Fed officials navigating uncharted waters. Key campaign promises, such as reworking trade agreements, imposing tariffs and enacting tax reform, could have sweeping impacts on the U.S. economy, particularly on inflation.</p>
<p>"A number of participants indicated they had incorporated placeholder assumptions regarding potential trade and immigration policy changes into their projections," the minutes state, highlighting the Fed's uncertainty about the fiscal environment ahead.</p>
<p>"The effects of potential changes in trade and immigration policy suggested that the process [of reaching the 2% inflation target] could take longer than previously anticipated," the minutes say.</p>
<h3 class="wp-block-heading">Inflation, Economic Projections Adjusted</h3>
<p>The Fed updated its economic projections at the December meeting, and they showed a slower pace of cuts through 2025.</p>
<p>The central bank now projects two 25-basis-point rate reductions next year, down from the four forecasted in September. By the end of 2025, the federal funds rate is expected to hover around 3.9%, with a further decline to 3.4% in 2026.</p>
<p>Notably, the Fed raised its inflation forecasts. Headline Personal Consumption Expenditure inflation for 2025 is now expected to reach 2.5% compared to a prior estimate of 2.1%. Core PCE inflation, which excludes volatile food and energy prices, is projected at 2.5%, up from 2.2%.</p>
<p><strong>Market Reactions</strong></p>
<p>Markets showed muted responses to the Fed minutes, suggesting the hawkish tone from the December meeting had already been priced in by investors.</p>
<p>The U.S. dollar index – as tracked by the <strong>Invesco DB USD Index Bullish Fund ETF </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) – held steady at the 109 level, maintaining its 0.4% intraday gain.</p>
<p>Equities experienced a modest relief rally, with the S&amp;P 500, tracked by <strong>SPDR S&amp;P 500 ETF Trust</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), reversing earlier losses to trade marginally higher for the session.</p>
<p>Treasury yields were largely unchanged. The 10-year yield hovered at 4.69%, while the 30-year yield remained stable at 4.93%, signaling little movement in bond markets.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42881085/is-labor-market-cooling-or-raising-fed-concerns-what-to-watch-in-fridays-jobs-report">Is Labor Market Cooling Or Raising Fed Concerns? What To Watch In Friday&#8217;s Jobs Report</a></strong></li>
</ul>
<p><em>Photo created using artificial intelligence via Midjourney. </em></p>


Currency ETFs

Econ #s

Economics

Federal Reserve

Markets

ETFs

PowerShares DB US Dollar Index Bullish Fund

Fed Minutes Reveal Inflation Jitters, Policymakers Signal Slower Interest Rate Easing Path Ahead

<p>Guggenheim  analyst Michael Morris   maintains Warner Music Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WMG#NASDAQ">WMG</a>) with a Buy and lowers the price target from $44 to $40.</p>


Guggenheim Maintains Buy on Warner Music Gr, Lowers Price Target to $40

<p>On Tuesday, Alger launched the <strong>Alger Russell Innovation ETF </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INVN#NYSE">INVN</a>), another addition to its lineup of funds aiming to cash in on <a href="https://www.benzinga.com/topic/etf">transformative market opportunities. </a></p>
<p>The <a href="https://www.prnewswire.com/news-releases/alger-and-ftse-russell-launch-the-alger-russell-innovation-etf-ticker-invn-to-capture-the-next-wave-of-market-disruptors-302342157.html">ETF </a>comes with an expense ratio of 0.55% and mirrors the Alger Russell Innovation Index, which focuses on innovative underdogs with high potential. At least 80% of the fund&#8217;s total assets are invested in securities of the Alger Russell Innovation Index, according to the fund&#8217;s prospectus.</p>
<p><strong>See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42878368/xrp-etf-very-soon-likely-next-after-bitcoin-and-ethereum-ripple-president-says">XRP ETF &#8216;Very Soon,&#8217; Likely Next After Bitcoin And Ethereum, Ripple President Says</a></strong></p>
<p><strong>BioMarin Pharmaceutical Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>), <strong>Teradata Corporation</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDC#NYSE">TDC</a>), and <strong>Bristol-Myers Squibb Company</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) are among the top holdings, accounting for 2.11%, 2.01%, and 2.03% as of Jan. 7. The fund&#8217;s portfolio consists of about 50 holdings.</p>
<p>The index uses a quantitative methodology to identify innovation-driven equities, shortlists them based on lower cash flow margins and then ranks them based on research and development expenditures. The top 50 companies on this ranking are then selected, with each stock constituting around 2% of the portfolio.</p>
<p><strong>Brad Neuman</strong>, CFA, Alger's Director of Market Strategy, thinks that this approach could bring innovation &#8220;out of the shadow of financial statements&#8221; and into accessible investment instruments.</p>
<p>The launch of INVN makes it the sixth Alger ETF available on U.S. markets. Among its other offerings, the <strong>Alger Mid Cap 40 ETF </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRTY#NYSE">FRTY</a>) stands out with over $70 million in assets under management.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/general/biotech/25/01/42882233/bird-flu-sparks-vaccine-stock-surge-etfs-to-watch-as-h5n1-outbreak-intensifies">Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies</a></strong></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


New ETFs

BMRN

FRTY

INVN

Alger Launches Russell Innovation ETF To Capitalize On Emerging Innovators

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>CVS Health</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CVS, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 17 uncommon options trades for CVS Health.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 52% bullish and 47%, bearish.</p>
<p>Out of all of the special options we uncovered, 7 are puts, for a total amount of $853,576, and 10 are calls, for a total amount of $1,325,759.</p>
<h3>Expected Price Movements</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $45.0 to $65.0 for CVS Health over the last 3 months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in CVS Health's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to CVS Health's substantial trades, within a strike price spectrum from $45.0 to $65.0 over the preceding 30 days.</p>
<h3>CVS Health Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736364670_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$1.68</td>
<td>$1.61</td>
<td>$1.62</td>
<td>$55.00</td>
<td>$567.0K</td>
<td>2.4K</td>
<td>3.6K</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$9.7</td>
<td>$9.35</td>
<td>$9.35</td>
<td>$45.00</td>
<td>$365.6K</td>
<td>2.2K</td>
<td>391</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$10.05</td>
<td>$10.0</td>
<td>$10.05</td>
<td>$52.50</td>
<td>$223.1K</td>
<td>36</td>
<td>224</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$4.6</td>
<td>$4.3</td>
<td>$4.6</td>
<td>$52.50</td>
<td>$161.9K</td>
<td>4.8K</td>
<td>674</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$9.4</td>
<td>$9.15</td>
<td>$9.15</td>
<td>$45.00</td>
<td>$154.6K</td>
<td>2.2K</td>
<td>730</td>
</tr>
</tbody>
</table>
</p>
<h3>About CVS Health</h3>
<p>CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.</p>
<p>In light of the recent options history for CVS Health, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>CVS Health's Current Market Status</h3>
<ul>
<li>With a trading volume of 7,320,414, the price of CVS is up by 0.02%, reaching $45.79.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 35 days from now.</li>
</ul>
<h3>What Analysts Are Saying About CVS Health</h3>
<p>A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $60.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Truist Securities persists with their Buy rating on CVS Health, maintaining a target price of $60. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for CVS Health, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Market Whales and Their Recent Bets on CVS Options

<p>Guggenheim  analyst Joseph Osha   initiates coverage on MasTec (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) with a Buy rating and announces Price Target of $195.</p>


Guggenheim Initiates Coverage On MasTec with Buy Rating, Announces Price Target of $195

<p>High-rolling investors have positioned themselves bearish on Cisco Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in CSCO often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 10 options trades for Cisco Systems. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 30% bullish and 70% bearish. Among all the options we identified, there was one put, amounting to $59,696, and 9 calls, totaling $725,211.</p>
<h3>What's The Price Target?</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $55.0 to $62.5 for Cisco Systems over the recent three months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Cisco Systems's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Cisco Systems's whale activity within a strike price range from $55.0 to $62.5 in the last 30 days. </p>
<h3>Cisco Systems Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736364664_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CSCO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$0.98</td>
<td>$0.82</td>
<td>$0.98</td>
<td>$62.50</td>
<td>$396.0K</td>
<td>8.3K</td>
<td>4.0K</td>
</tr>
<tr>
<td>CSCO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$10.25</td>
<td>$9.9</td>
<td>$10.25</td>
<td>$55.00</td>
<td>$63.5K</td>
<td>590</td>
<td>62</td>
</tr>
<tr>
<td>CSCO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.48</td>
<td>$1.43</td>
<td>$1.48</td>
<td>$57.50</td>
<td>$61.5K</td>
<td>22.6K</td>
<td>475</td>
</tr>
<tr>
<td>CSCO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$1.84</td>
<td>$1.82</td>
<td>$1.82</td>
<td>$55.00</td>
<td>$59.6K</td>
<td>6.0K</td>
<td>329</td>
</tr>
<tr>
<td>CSCO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/14/25</td>
<td>$0.87</td>
<td>$0.71</td>
<td>$0.71</td>
<td>$62.00</td>
<td>$48.4K</td>
<td>66</td>
<td>1.5K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Cisco Systems</h3>
<p>Cisco Systems is the largest provider of networking equipment in the world and one of the largest software companies in the world. Its largest businesses are selling networking hardware and software (where it has leading market shares) and cybersecurity software such as firewalls. It also has collaboration products, like its Webex suite, and observability tools. It primarily outsources its manufacturing to third parties and has a large sales and marketing staff-25,000 strong across 90 countries. Overall, Cisco employs 80,000 people and sells its products globally.</p>
<p>After a thorough review of the options trading surrounding Cisco Systems, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Present Market Standing of Cisco Systems</h3>
<ul>
<li>With a volume of 5,539,523, the price of CSCO is up 0.19% at $59.04. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 35 days.</li>
</ul>
<h3>Expert Opinions on Cisco Systems</h3>
<p>1 market experts have recently issued ratings for this stock, with a consensus target price of $68.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Overweight rating on Cisco Systems with a target price of $68. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Cisco Systems with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


CSCO

Behind the Scenes of Cisco Systems's Latest Options Trends

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Qualcomm</strong>.</p>
<p>Looking at options history for Qualcomm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) we detected 11 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 36% of the investors opened trades with bullish expectations and 27% with bearish.</p>
<p>From the overall spotted trades, 5 are puts, for a total amount of $256,157 and 6, calls, for a total amount of $664,565.</p>
<h3>Predicted Price Range</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $80.0 to $175.0 for Qualcomm over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Qualcomm's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Qualcomm's whale trades within a strike price range from $80.0 to $175.0 in the last 30 days. </p>
<h3>Qualcomm Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736364659_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>QCOM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$15.55</td>
<td>$15.15</td>
<td>$15.4</td>
<td>$160.00</td>
<td>$154.0K</td>
<td>1.2K</td>
<td align="right">109</td>
</tr>
<tr>
<td>QCOM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$84.6</td>
<td>$81.4</td>
<td>$83.15</td>
<td>$80.00</td>
<td>$141.3K</td>
<td>30</td>
<td align="right">0</td>
</tr>
<tr>
<td>QCOM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$84.45</td>
<td>$81.5</td>
<td>$83.0</td>
<td>$80.00</td>
<td>$141.1K</td>
<td>30</td>
<td align="right">34</td>
</tr>
<tr>
<td>QCOM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$9.65</td>
<td>$9.65</td>
<td>$9.65</td>
<td>$175.00</td>
<td>$96.5K</td>
<td>798</td>
<td align="right">100</td>
</tr>
<tr>
<td>QCOM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$3.7</td>
<td>$3.45</td>
<td>$3.5</td>
<td>$157.50</td>
<td>$87.5K</td>
<td>2.0K</td>
<td align="right">253</td>
</tr>
</tbody>
</table>
</p>
<h3>About Qualcomm</h3>
<p>Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G, 4G, and 5G networks. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones, as well as chips into automotive and Internet of Things markets.</p>
<p>In light of the recent options history for Qualcomm, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Where Is Qualcomm Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 2,808,029, with QCOM's price down by -0.51%, positioned at $159.7.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 21 days.</li>
</ul>
<h3>Professional Analyst Ratings for Qualcomm</h3>
<p>A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $215.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Mizuho continues to hold a Outperform rating for Qualcomm, targeting a price of $215. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Qualcomm with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


QCOM

Looking At Qualcomm's Recent Unusual Options Activity

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Regional Health Props</strong> (NYSEMKT:<span><a href="https://investorplace.com/stock-quotes/rhe-stock-quote/"><strong>RHE</strong></a></span>) just reported results for the fourth quarter of 2023.</p><ul><li>Regional Health Props reported earnings per share of -13 cents.</li><li>The company reported revenue of $4.52 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/04/rhe-stock-earnings-regional-health-props-for-q4-of-2023/">RHE Stock Earnings: Regional Health Props Reported Results for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

RHE Stock Earnings: Regional Health Props Reported Results for Q4 2023

Regional Health Properties (RHE) just unveiled an update. Regional Health Properties, Inc. has appointed Heather L. Pittard as their new Chief Acco...

Regional Health Properties Names New Chief Accounting Officer

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Regional Health Props</strong> (NYSEMKT:<span><a href="https://investorplace.com/stock-quotes/rhe-stock-quote/"><strong>RHE</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>Regional Health Props reported earnings per share of -52 cents.</li><li>The company reported revenue of $4.13 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/07/rhe-stock-earnings-regional-health-props-for-q1-of-2024/">RHE Stock Earnings: Regional Health Props Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

RHE Stock Earnings: Regional Health Props Reported Results for Q1 2024

Regional Health Properties (RHE) announced that, on November 11, 2024, NYSE American LLC publicly announced and provided a notice to the Company th...

Regional Health Properties receives NYSE American notice of delisting

Regional Health Properties GAAP EPS of -$0.52, revenue of $4.23M

Regional Health Properties (RHE) and SunLink Health Systems (SSY) jointly announced today that they have entered into a definitive agreement and pl...

Regional Health, SunLink Health to merge in all-stock transaction

Regional Health Properties to acquire SunLink Health in an all-stock deal

Press Releases

Regional Health Properties, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal

Regional Health Properties Reports Third Quarter 2024 Financial Results

REGIONAL HEALTH PROPERTIES AND SUNLINK HEALTH SYSTEMS TO MERGE IN AN ALL-STOCK TRANSACTION

RHE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Regional Health Properties, Inc. Is Fair to Shareholders

Legal

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Predictive Oncology Inc. (Nasdaq - POAI), SunLink Health Systems, Inc. (NYSE American - SSY), Universal Stainless & Alloy Products, Inc. (Nasdaq - USAP), Patterson Companies, Inc. (Nasdaq - PDCO)

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SSY, FUBO, RHE, POAI on Behalf of Shareholders

SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates RHE, FUBO, POAI on Behalf of Shareholders

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Regional Health Properties, Inc. - RHE

SUNLINK HEALTH INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of SunLink Health Systems, Inc. - SSY

Comments

Regional Health Props

空売り

Regional Health Props (AMEX:RHE) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル